At ROVI we don't believe in borders

We bet on the internationalization of our main product, Bemiparin, as one of our long-term growth engines. This is corroborated by our growth in some countries where we were already present and our entry into new markets, such as China, Brazil, Argentina and the Philippines.

Reaching more countries and more people

ISM

To date, as a result of our 20 international partners our main product, BEMIPARIN, is now present in more than 55 countries.

ISM

With our Enoxaparin Biosimilar, we hope to increase our presence in Europe, the United States and emerging countries.